$SUPER INC(SMCI)$ $SUPER INC(S

1
Comment
Favorite

Nackky
2023-09-12

$SUPER INC(SMCI)$ $SUPER INC(SMCI)$ $SUPER INC(SMCI)$

Crinetics Soars 73% As Lead Asset Succeeds in Phase 3 Trial for Acromegaly

$Crinetics Pharmaceuticals(CRNX)$ added 73.89% pre-market Monday after announcing that its lead candidate, paltusotine, achieved the primary endpoint and all secondary endpoints in a Phase 3 trial for

Crinetics Soars 73% As Lead Asset Succeeds in Phase 3 Trial for Acromegaly

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":218861176041640,"tweetId":"218861176041640","gmtCreate":1694458770674,"gmtModify":1694458773422,"author":{"id":4149970614197132,"authorId":4149970614197132,"authorIdStr":"4149970614197132","name":"Nackky","avatar":"https://community-static.tradeup.com/news/762717a8a75a2e9ebe6d882a1e937226","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p><a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a><a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a><a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a></p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a><a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a><a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a></p></body></html>","text":"$SUPER INC(SMCI)$ $SUPER INC(SMCI)$ $SUPER INC(SMCI)$","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/218861176041640","repostId":1155629873,"repostType":2,"repost":{"id":"1155629873","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1694440135,"share":"https://www.laohu8.com/m/news/1155629873?lang=&edition=full","pubTime":"2023-09-11 21:48","market":"us","language":"en","title":"Crinetics Soars 73% As Lead Asset Succeeds in Phase 3 Trial for Acromegaly","url":"https://stock-news.laohu8.com/highlight/detail?id=1155629873","media":"Tiger Newspress","summary":"$Crinetics Pharmaceuticals(CRNX)$ added 73.89% pre-market Monday after announcing that its lead candidate, paltusotine, achieved the primary endpoint and all secondary endpoints in a Phase 3 trial for","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/CRNX\">Crinetics Pharmaceuticals</a> added 73.89% pre-market Monday after announcing that its lead candidate, paltusotine, achieved the primary endpoint and all secondary endpoints in a Phase 3 trial for patients with the rare disease acromegaly.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/73fd1a760547b221377961286576b27b\" tg-width=\"808\" tg-height=\"630\"/></p><p>The PATHFNDR-1 study enrolled 58 adults with acromegaly, characterized by excessive growth hormone secretion. After switching from standard-of-care, they received once-daily oral paltusotine or a placebo for 36 weeks .</p><p>The trial met statistical significance (p&lt;0.0001) for the primary endpoint as 83% of patients on paltusotine maintained an insulin-like growth factor 1 (IGF-1) level ≤ 1.0 times the upper limit of normal, compared to 4% on placebo.</p><p>All secondary endpoints of the trial also achieved statistical significance. Regarding safety, the proportion of patients with at least one treatment-emergent adverse event (TEAE) stood at 80% and 100% for the on-drug and off-drug arms, respectively.</p><p>Crinetics intends to seek U.S. regulatory approval for paltusotine in 2024, subject to positive results from PATHFNDR-2, an ongoing Phase 3 study for the drug targeted at untreated acromegaly patients. That trial is fully enrolled and is expected to generate early data in Q1 2024.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crinetics Soars 73% As Lead Asset Succeeds in Phase 3 Trial for Acromegaly</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrinetics Soars 73% As Lead Asset Succeeds in Phase 3 Trial for Acromegaly\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2023-09-11 21:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/CRNX\">Crinetics Pharmaceuticals</a> added 73.89% pre-market Monday after announcing that its lead candidate, paltusotine, achieved the primary endpoint and all secondary endpoints in a Phase 3 trial for patients with the rare disease acromegaly.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/73fd1a760547b221377961286576b27b\" tg-width=\"808\" tg-height=\"630\"/></p><p>The PATHFNDR-1 study enrolled 58 adults with acromegaly, characterized by excessive growth hormone secretion. After switching from standard-of-care, they received once-daily oral paltusotine or a placebo for 36 weeks .</p><p>The trial met statistical significance (p&lt;0.0001) for the primary endpoint as 83% of patients on paltusotine maintained an insulin-like growth factor 1 (IGF-1) level ≤ 1.0 times the upper limit of normal, compared to 4% on placebo.</p><p>All secondary endpoints of the trial also achieved statistical significance. Regarding safety, the proportion of patients with at least one treatment-emergent adverse event (TEAE) stood at 80% and 100% for the on-drug and off-drug arms, respectively.</p><p>Crinetics intends to seek U.S. regulatory approval for paltusotine in 2024, subject to positive results from PATHFNDR-2, an ongoing Phase 3 study for the drug targeted at untreated acromegaly patients. That trial is fully enrolled and is expected to generate early data in Q1 2024.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRNX":"Crinetics Pharmaceuticals Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155629873","content_text":"Crinetics Pharmaceuticals added 73.89% pre-market Monday after announcing that its lead candidate, paltusotine, achieved the primary endpoint and all secondary endpoints in a Phase 3 trial for patients with the rare disease acromegaly.The PATHFNDR-1 study enrolled 58 adults with acromegaly, characterized by excessive growth hormone secretion. After switching from standard-of-care, they received once-daily oral paltusotine or a placebo for 36 weeks .The trial met statistical significance (p<0.0001) for the primary endpoint as 83% of patients on paltusotine maintained an insulin-like growth factor 1 (IGF-1) level ≤ 1.0 times the upper limit of normal, compared to 4% on placebo.All secondary endpoints of the trial also achieved statistical significance. Regarding safety, the proportion of patients with at least one treatment-emergent adverse event (TEAE) stood at 80% and 100% for the on-drug and off-drug arms, respectively.Crinetics intends to seek U.S. regulatory approval for paltusotine in 2024, subject to positive results from PATHFNDR-2, an ongoing Phase 3 study for the drug targeted at untreated acromegaly patients. That trial is fully enrolled and is expected to generate early data in Q1 2024.","news_type":1},"isVote":1,"tweetType":1,"viewCount":211,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["SMCI"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":48,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}